• Events
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • January 23, 2020
  • Author: EURETINA Brief

Strategy aims to overcome RP heterogeneity using gene therapy treatment with dominant retinitis pigmentosa

Researchers at the Scheie Eye Institute, University of Pennsylvania, has reported that a mutation-independent strategy for treating autosomal dominant retinitis pigmentosa (adRP) prevents photoreceptor cell death in the retina.  The research team developed a gene therapy approach using a single adeno-associated viral (AAV) system delivering the experimental treatment to a large animal model of RP.  Sub-retinal injections provided a nearly complete suppression of endogenous rhodopsin, then replacing rhodopsin cDNA resulting in up to 30% of normal rhodopsin protein levels.  The study is now posed to pave the way for gene therapy trials within an estimated 5 years.

 

The technology takes advantage of developing a mutation-independent gene therapy previously identified by researchers in Trinity College, University of Dublin.  In the earlier research, every 3 bases of DNA specify an amino acid and a string of amino acids making up a working protein, such as rhodopsin.  However, the third base of each group of 3 can be changed without altering the structure of the protein, always termed as the “degeneracy of the genetic code”.  The strategy takes advantage of this feature of the human genome by using gene editing to knock out all copies of a given gene and replacing them with a functional gene copy changed at several third base sites. The new replacement functions normally and cannot be knocked down by genetic editing using either antisense, ribozymes, RNAi or CRISPR technology.  The retina represents an ideal target for gene medicine.  It is a readily accessible tissue within a confined chamber composed of mostly non-replicating cells existing in an immune privileged environment.  These characteristics represent significant advantages over other gene medicine targets.

 

Additionally, there are over 150 different mutations in the rhodopsin gene that may cause retinitis pigmentosa.  Consequently, a gene medicine approach for such a disease could require 150 different therapies.  The suppression and replacement approach overcomes this difficulty through allowing a single treatment to treat all 150 different mutations (or patients). A significant advantage of this mechanism is that it is entirely independent of an individual’s mutation.  Rather than focusing on each specific mutation, this approach uses a set of molecular “scissors” (antisense/RNAi/CRISPR) to remove all copies of a particular RNA transcript associated with disease. At the same time as the mutated and normal RNA transcripts are removed a new functioning gene is provided, altered at one or more bases, such that its transcript escapes excision by the molecular scissors.  This approach circumvents the necessity to address individual mutations and represents the core competitive advantage, i.e., suppression and replacement.  This innovative technology now permits the potential treatment of a wide range of dominant disorders which previously were both clinically and economically unviable.

PrevPrevious
NextNext

You might also like

Educational Debate 5: A May Double Debate! (9 May, 2022)

Read More

EURETINA Case Club: Series 1, Episode 6 with Prof Paolo Lanzetta (27 Apr, 2022)

Read More

EURETINA Session: Tumours

Read More

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login